The FDA has approved Steqeyma® (ustekinumab-stba), a biosimilar to Stelara®, for the treatment of various chronic ...

Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® received MHRA approval for both subcutaneous and intravenous formulations, to ...

The efficacy and safety of a proposed biosimilar and ustekinumab are similar among adults with moderate to severe plaque psoriasis.

Regulatory ApprovalFormycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 15.01.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...

Marks the Third Year Since the Launch of the First US Biosimilar Market ReportINCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Samsung ...

Formycon and Fresenius Kabi secure UK approval for Otulfi, a ustekinumab biosimilar targeting inflammatory conditions.

Biocon's biosimilar Ustekinumab receives regulatory approval in Japan, with Yoshindo Inc. handling commercialization and ...

Ustekinumab-stba is approved for multiple conditions, showing comparable efficacy and safety to Stelara in clinical trials. The biosimilar will be available in subcutaneous and intravenous forms ...

UCB, a global biopharmaceutical company, announced today that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX® (bimekizumab-bkzx) is now available. These ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...